Skip to main content


Victor A. Levin, MD, is currently Emeritus Professor of Neuro-Oncology at the University of Texas M.D. Anderson Cancer Center, Clinical Professor in the Department of Neurosurgery at the University of California San Francisco Medical School, and a Neuro-Oncology pool Physician at the Kaiser Permanente Redwood City Hospital.  In addition, he is Senior Medical Advisor to Orbus Therapeutics, Inc. and the STELLAR Study for the treatment of recurrent anaplastic astrocytoma; DMC Chair for Bristol Myers Squibb CNS immunotherapy trials; and scientific advisor to more than 25 large and small pharmaceutical and device companies and philanthropic groups over the decades.

In addition, over his academic career he has held academic positions as Professor in the Department of Neurosurgery and Department of Pharmacology, University of California - San Francisco School of Medicine (UCSF) in 1981−1987; Professor, Department Pharmaceutical Chemistry, University of California - San Francisco, School of Pharmacy in 1981−1988; and Professor, Department of Neuro-Oncology and held the Bernard W. Biedenharn Chair for Cancer Research Medicine, The University of Texas M. D. Anderson Cancer Center (UT MDACC) in 1988−2009. He has also held the following positions as Chief, Neuro-Oncology Service, Brain Tumor Research Center, Department of Neurological Surgery, UCSF in 1977−1988; Chairman, Experimental Cancer Treatment Group, Northern California Cancer Center (NCCP) in 1980−1987; Associate Director, Brain Tumor Research Center, UCSF in 1980−1988; Associate Director for Laboratory Research, NCCP in 1983−1988; and Co-Director, Brain Tumor Center, UT MDACC in 1993−1999. He was also the Founder, with Charles B. Wilson, MD, of the International Conference on Brain Tumor Research & Therapy and organizer of the conferences in 1975, 1979, and 1981

Over his nearly 50 year career, he has received many awards including a 5-year American Cancer Society Faculty Award; Medal of the Medical Faculty of Tokyo University, Farber Foundation Award in Neuro-Oncology, David A. Frommer Memorial Lecture in Neuro-Oncology, Fred Plum Lecturer, Heath Memorial Award for Cancer Care; The First Annual Takao Hoshino Lecturer at both UCSF and at the Japan Neurological Society Annual Meeting; and the Society for Neuro-Oncology Gold Medal Award for Extraordinary Achievement. He has held many NIH, philanthropic, institutional, and pharmaceutical company grants including principal investigator on the first National Cancer Cooperative Drug Discovery Group (NCDDG) in 1983 that he renewed 3 times over 17 years as well as the first PO1 for glioma research funded at the UT MDACC in 1996. He was the primary founder of the Society for Neuro-Oncology and its first president in 1995 and a founder of one early stage (Signase) and two late stage pharmaceutical companies (VBL Pharmaceuticals and Orbus Therapeutics).  He has written 395 peer-reviewed papers, invited articles, book chapters, and books as well as 2 op-ed newspaper articles and is cited on 9 patents.